Education
About Us
Working with TipRanks
Follow Us
Prokidney Corp. (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$2.24
-$0.14(-7.65%)
At close: 4:00 PM EST
$2.24
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)781.09K
Market Cap
$673.87M
Enterprise Value$539.27M
Total Cash (Recent Filing)$271.73M
Total Debt (Recent Filing)$4.24M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding141,545,440
10 Day Avg. Volume454,924
30 Day Avg. Volume781,091
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)-0.17
Price to Sales (P/S)2177.35
P/FCF Ratio-1.06
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue724.83
Enterprise Value/Gross Profit-824.57
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$5.33Price Target Upside137.95% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.6
Revenue Forecast (FY)$83.33K
Bulls Say, Bears Say
Bulls Say
Accelerated Regulatory PathwayPlanned surrogate-endpoint readout could support an accelerated regulatory filing, offering a faster route to market if surrogate results meet approval criteria.
Cost And Execution EfficiencyOptimizing enrollment is expected to lower development costs and simplify trial execution, which may lead to cleaner and timelier study outcomes.
Patient Enrollment StrengthStrong patient enrollment and unusually high participation in the cell therapy study reduce execution risk and increase confidence in meeting upcoming study milestones.
Bears Say
Confirmatory Trial DurationReducing total patient enrollment while keeping the same event targets will lengthen the time needed to reach confirmatory results, delaying full approval certainty.
Event-driven Completion RiskRelying on the same number of events with fewer enrollees concentrates risk on event accrual and may complicate predictable trial completion.
Surrogate Endpoint DependencyRegulatory approval depends on meeting the surrogate endpoint threshold, creating outcome risk if the surrogate fails to demonstrate the required benefit.
ProKidney News
PROK FAQ
What was Prokidney Corp.’s price range in the past 12 months?
Prokidney Corp. lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is Prokidney Corp.’s market cap?
Prokidney Corp.’s market cap is $673.87M.
When is Prokidney Corp.’s upcoming earnings report date?
Prokidney Corp.’s upcoming earnings report date is May 08, 2026 which is in 67 days.
How were Prokidney Corp.’s earnings last quarter?
Prokidney Corp. released its earnings results on Nov 18, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.013.
Is Prokidney Corp. overvalued?
According to Wall Street analysts Prokidney Corp.’s price is currently Undervalued.
Does Prokidney Corp. pay dividends?
Prokidney Corp. does not currently pay dividends.
What is Prokidney Corp.’s EPS estimate?
Prokidney Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prokidney Corp. have?
Prokidney Corp. has 141,545,440 shares outstanding.
What happened to Prokidney Corp.’s price movement after its last earnings report?
Prokidney Corp. reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of Prokidney Corp.?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.33 (137.95% Upside)
$5.33 (137.95% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
78.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.94%
Trailing 12-Months
Company Description
Prokidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$5.33
▲(137.95% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---